GILD

Gilead Sciences
D

GILD

156.070
USD
-1.15
(-0.73%)
Market Closed
Last updated: · Delayed 15 min
Volume
217,264
EPS
-0
Div Yield
2.08
P/E
-59
Market Cap
193,519,801,041
Overview
Related Instruments
ABBV
ABBV
D
ABBVIE
285.67
0.71(0.25%)
AMGN
AMGN
D
Amgen
439.14
-8.24(-1.84%)
AZN
AZN
D
AstraZeneca PLC
171.490
-1.090(-0.63%)
BMY
BMY
D
Bristol-Myers Squibb Co
61.480
-1.530(-2.43%)
GSK
GSK
D
GSK plc
50.750
-0.460(-0.90%)
LLY
LLY
D
Eli Lilly & Co
1,273.75
-33.51(-2.56%)
MRK
MRK
D
Merck & Co
145.270
-1.970(-1.34%)
NVS
NVS
D
Novartis AG
151.120
-5.170(-3.31%)
PFE
PFE
D
Pfizer
30.015
-0.400(-1.32%)
REGN
REGN
D
Regeneron Pharmaceuticals
805.40
-14.20(-1.73%)
SNY
SNY
D
Sanofi ADS
41.585
-0.365(-0.87%)
More

Title: Gilead Sciences

Sector: Healthcare
Industry: Drug Manufacturers - General
Gilead Sciences Inc. is an American biopharmaceutical firm that was founded in 1987 under the name Oligogen by Michael L. Riordan. The company specializes in the research, development and sale of medicines in underdeveloped research areas. To this end, the company engages its research in such areas as the human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under many brand names, including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Sovaldi and more. The company is headquartered in Foster, California, and its stock is measured on the NASDAQ Biotechnology Index and the S&P 500 Index.
Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.